Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC vs TACE with Regorafenib and ICI in Advanced HCC
NCT05233358Unknown
- Sponsor
- Lishui City Central Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Lishui City Central Hospital. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05233358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233358.